LM Xu

Dr. LM Xu


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 March 2020 in Leukemia
Verified
Journal Article
Open access
PDF file
SCSi-Ye Chen
Si-Ye Chen
YYYong Yang
Yong Yang
SQShu-Nan Qi
Shu-Nan Qi
YWYing Wang
Ying Wang
CHChen Hu
Chen Hu
YLYexiong Li
Yexiong Li
Derived from our original nomogram study by using the risk variables from multivariable analyses in the derivation cohort of 1383 patients with extranodal NK/T-cell lymphoma, nasal-type (ENKTCL) who were mostly treated with anthracycline-based chemotherapy, we propose an easily used nomogram-revised risk index (NRI), validated it and compared with Ann Arbor staging, the International Prognostic Index (IPI), Korean Prognostic Index (KPI), and prognostic index of natural killer lymphoma (PINK) for overall survival (OS) prediction by examining calibration, discrimination, and decision curve analysis in a validation cohort of 1582 patients primarily treated with non-anthracycline-based chemotherapy. The calibration of the NRI showed satisfactory for predicting 3- and 5-year OS in the validation cohort. The Harrell’s C-index and integrated Brier score (IBS) of the NRI for OS prediction demonstrated a better performance than that of the Ann Arbor staging system, IPI, KPI, and PINK. Decision curve analysis of the NRI also showed a superior outcome. The NRI is a promising tool for stratifying patients with ENKTCL into risk groups for designing clinical trials and for selecting appropriate individualized treatment.

17 September 2020 in Leukemia
Verified
Journal Article
Open access
PDF file
YYYong Yang
Yong Yang
YWYing Wang
Ying Wang
XLXin Liu
Xin Liu
XHXia He
Xia He
LZLi-Ling Zhang
Li-Ling Zhang
YLYexiong Li
Yexiong Li
Limited evidence supports the use of early endpoints to evaluate the success of initial treatment of extranodal NK/T-cell lymphoma (ENKTCL) in the modern era. We aim to analyze progression-free survival at 24 months (PFS24) and subsequent overall survival (OS) in a large-scale multicenter cohort of patients. 1790 patients were included from the China Lymphoma Collaborative Group (CLCG) database. Subsequent OS was defined from the time of PFS24 or progression within 24 months to death. OS was compared with age- and sex-matched general Chinese population using expected survival and standardized mortality ratio (SMR). Patients who did not achieve PFS24 had a median OS of 5.3 months after progression, with 5-year OS rate of 19.2% and the SMR of 71.4 (95% CI, 62.9–81.1). In contrast, 74% patients achieved PFS24, and the SMR after achieving PFS24 was 1.77 (95% CI, 1.34–2.34). The observed OS rate after PFS24 versus expected OS rate at 5 years was 92.2% versus 94.3%. Similarly, superior outcomes following PFS24 were observed in early-stage patients (5-year OS rate, 92.9%). Patients achieving PFS24 had excellent outcome, whereas patients exhibiting earlier progression had a poor survival. These marked differences suggest that PFS24 may be used for study design and risk stratification in ENKTCL.

1 February 2019 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
YZYirui Zhai
Yirui Zhai
HMHonglian Ma
Honglian Ma
ZHZhouguang Hui
Zhouguang Hui
LZLujun Zhao
Lujun Zhao
DLDongming Li
Dongming Li
LWLuhua Wang
Luhua Wang

23 August 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
LXLM Xu
LM Xu
CCChingyun Cheng
Chingyun Cheng
MKMinglei Kang
Minglei Kang
JLJing Luo
Jing Luo
LGLin-Lin Gong
Lin-Lin Gong
PWPing Wang
Ping Wang
There has been no previous study on the efficacy of the thoracic radiotherapy (TRT) in oligometastatic or polymetastatic extensive stage small-cell lung cancer (ES-SCLC) to the overall survival (OS). In a group of 270 ES-SCLC cases retrospective study, 78 patients (28.9%) had oligometastases and 192 (71.1%) had polymetastases, among which 51 oligometastatic patients (65.4%) and 93 polymetastatic patients (51.6%) received TRT. Propensity score matching (PSM) was utilized. The 2-year OS, progression free survival (PFS) and local control (LC) in oligometastatic and polymetastatic patients were 22.8% and 4.5% (p < 0.001), 12.0% and 3.8% (p < 0.001), and 36.7% and 6.1% (p < 0.001), respectively. The 2-year OS in oligometastatic patients with the chemotherapy + radiotherapy and chemotherapy alone were 25.2% and 12.7% (p = 0.002), in contrast to 10.0% and 6.8% (p = 0.030) in polymetastatic patients. The estimated hazard ratios for survival were 2.9 and 1.7 for both oligometastatic and polymetastatic patients with radiotherapy. The polymetastatic group has a lower LC (6.1% v.s. 36.7%, (p < 0.001)), due to polymetastases patients receiving involved-sites radiotherapy with low dose schemas. TRT improved OS of patients with oligometastases and polymetastases. Our study demonstrated that aggressive TRT might be a suitable addition of chemotherapy when treating ES-SCLC patients with oligometastases and polymetastases.

1 January 2020 in Journal of Cancer
Verified
Journal Article
Open access
YYYa-Jing Yuan
Ya-Jing Yuan
Yao SunYao Sun
Yao Sun
RGRong Gao
Rong Gao
ZYZhen-Zhen Yin
Zhen-Zhen Yin
ZYZhi-Yong Yuan
Zhi-Yong Yuan
LXLM Xu
LM Xu
Lung cancer is a type of malignant tumor with high morbidity and mortality. Due to its complicated etiology and clinical manifestations, no significant therapeutic advance has been made. Lung squamous cell carcinoma (LSCC) is the most common type of lung cancer. To combat this disease, novel therapeutic targets are badly requirement. ASPM (Abnormal spindle-like microcephaly-associated protein) is involved in multiple cellular or developmental processes, such as neurogenesis and brain growth. ASPM is also reported widely expressed in multiple tumor tissues and involved in the development and progression of several cancers including lung cancer. However, the potential role on ASPM on LSCC is still unclear. In this study, we reported that ASPM was related to the poor prognosis of patients with lung squamous cell carcinoma. Our results further showed that ASPM depletion dramatically inhibited the proliferation of LSCC cells, consistent with the obviously decreased of cyclin D1(CCND1) and cyclin dependent kinases 4 (CDK4) expression. In vivo assays further confirmed ASPM ablation markedly blocked tumor growth in vivo compared with control. In addition, a co-expression was found between ASPM and CDK4 in human tumor tissues. Taken together, our data provides strong evidence that ASPM promotes lung squamous cell carcinoma proliferation in vitro and in vivo, and indicates its potential role as a LSCC therapeutic target.

24 October 2018 in Cancer Medicine
Verified
Journal Article
Open access
PDF file
BCBo Chen
Bo Chen
SZSu‐Yu Zhu
Su‐Yu Zhu
MSMei Shi
Mei Shi
HSHang Su
Hang Su
YWYing Wang
Ying Wang
YLYexiong Li
Yexiong Li
Background: The purpose of this study was to determine the curability of early‐stage extranodal nasal‐type NK/T‐cell lymphoma (NKTCL) in response to radiotherapy and non‐anthracycline‐based chemotherapy in elderly patients.Methods: In this multicenter study from the China Lymphoma Collaborative Group (CLCG) database, 321 elderly patients with early‐stage NKTCL were retrospectively reviewed. Patients received radiotherapy alone (n = 87), chemotherapy alone (n = 59), or combined modality therapy (CMT, n = 175). Patients were classified into low‐ or high‐risk groups using four prognostic factors. Observed survival in the study cohort vs expected survival in age‐ and sex‐matched individuals from the general Chinese population was plotted using a conditional approach and subsequently compared using a standardized mortality ratio (SMR).Results: Radiotherapy conveyed a favorable prognosis and significantly improved survival compared to chemotherapy alone. The 5‐year overall survival (OS) and progression‐free survival (PFS) were 61.2% and 56.4%, respectively, for radiotherapy compared with 44.7% and 38.3%, respectively, for chemotherapy alone (P < 0.001). The combination of a non‐anthracycline‐based chemotherapy regimen and radiotherapy significantly improved PFS compared to combination of an anthracycline‐based chemotherapy regimen and radiotherapy (71.2% vs 44.2%, P = 0.017). Low‐risk patients following radiotherapy (SMR, 0.703; P = 0.203) and high‐risk patients who achieved PFS at 24 months (SMR, 1.490; P = 0.111) after radiotherapy showed survival equivalent to the general Chinese population.Conclusions: Our findings indicate a favorable curability for this malignancy in response to radiotherapy and non‐anthracycline‐based chemotherapy, providing a risk‐adapted follow‐up and counsel scheme in elderly patients.